About the Event
Please join Dr. Brian Levy, CEO of InflammX, and Andrew Gitkin, managing director and co-head of Health Care Investment Banking at Raymond James as they discuss the company and its new drug, Xiflam, a once-a-day pill that is being developed to treat the nearly 15 million Americans who suffer from dry age-related macular degeneration (AMD) and Diabetic Eye Disease.
Mr. Gitkin has 15-years of experience leading life sciences and biotechnology investment practices at companies that include Piper Jaffray, Moelis & Co, and Tavistock. This gives him a unique perspective with which to view InflammX and the opportunity Xiflam represents in the large and growing sector.
Xiflam is an orally administered small molecule which readily crosses the blood-retina barrier to treat ocular inflammation. Currently, there’s no treatment for Dry AMD and the standard of care for Diabetic Eye Disease requires monthly injections into the eye. Adding insult to injury, the treatment is only 50% effective for those who get the shot. Even with these obvious limitations, consumers spend $11.5B per year on the treatment.
Join our webinar with Dr. Levy and Mr. Gitkin as they discuss how Xiflam is poised to disrupt this $11.5B industry.